DE60127237T2 - Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie - Google Patents

Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie Download PDF

Info

Publication number
DE60127237T2
DE60127237T2 DE60127237T DE60127237T DE60127237T2 DE 60127237 T2 DE60127237 T2 DE 60127237T2 DE 60127237 T DE60127237 T DE 60127237T DE 60127237 T DE60127237 T DE 60127237T DE 60127237 T2 DE60127237 T2 DE 60127237T2
Authority
DE
Germany
Prior art keywords
ige
canine
antibody
serum
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60127237T
Other languages
German (de)
English (en)
Other versions
DE60127237D1 (de
Inventor
Robert L. Gorham LAWTON
Ashok P. Scarborough AIYAPPA
Wendy W. Shaker Heights LIU
Brion Cumberland Mermer
Hongliang Scarborough GUO
Eugene R. Portland KRAH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Publication of DE60127237D1 publication Critical patent/DE60127237D1/de
Application granted granted Critical
Publication of DE60127237T2 publication Critical patent/DE60127237T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE60127237T 2000-02-01 2001-01-30 Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie Expired - Lifetime DE60127237T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17962900P 2000-02-01 2000-02-01
US179629P 2000-02-01
US592998 2000-06-12
US09/592,998 US6504013B1 (en) 2000-02-01 2000-06-12 Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
PCT/US2001/002924 WO2001057090A1 (en) 2000-02-01 2001-01-30 Canine allergy therapeutic recombinant chimeric anti-ige monoclonal antibody

Publications (2)

Publication Number Publication Date
DE60127237D1 DE60127237D1 (de) 2007-04-26
DE60127237T2 true DE60127237T2 (de) 2007-12-20

Family

ID=26875491

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127237T Expired - Lifetime DE60127237T2 (de) 2000-02-01 2001-01-30 Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie

Country Status (6)

Country Link
US (1) US6504013B1 (https=)
EP (1) EP1254180B1 (https=)
JP (1) JP4605973B2 (https=)
AU (1) AU2001233102A1 (https=)
DE (1) DE60127237T2 (https=)
WO (1) WO2001057090A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
WO2002066602A2 (en) * 2001-01-03 2002-08-29 Heska Corporation Detection of allergen-specific ige
EP1485126A4 (en) * 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
ES2655912T3 (es) * 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
EP1733232A1 (en) * 2004-03-23 2006-12-20 Quidel Corporation Hybrid phase lateral flow assay
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
JP2006151880A (ja) * 2004-11-30 2006-06-15 Asahi Breweries Ltd 抗イヌＩｇＥモノクローナル抗体、その製造法および用途
AU2006223180B2 (en) 2005-03-11 2011-11-24 Wyeth Llc A method of weak partitioning chromatography
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
US9388236B2 (en) 2007-07-09 2016-07-12 Nestec Sa Methods for reducing allergies caused by environmental allergens
HUE032078T2 (en) * 2007-07-09 2017-08-28 Nestec Sa Procedure for reducing allergies caused by environmental allergens
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
JP6199054B2 (ja) * 2013-03-19 2017-09-20 公益財団法人かずさＤｎａ研究所 抗イヌＩｇＥモノクローナル抗体並びに抗イヌＩｇＥモノクローナル抗体の重鎖可変領域及び軽鎖可変領域
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
CN109143137B (zh) * 2018-06-14 2020-09-29 国电南瑞科技股份有限公司 一种发电机pmu装置测量精度提升方法
WO2021195560A1 (en) * 2020-03-27 2021-09-30 Aquavit Pharmaceuticals, Inc, Methods of detecting allergic reactions in subjects using microchannel delivery devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006138A1 (en) 1987-12-31 1989-07-13 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
JP2811096B2 (ja) * 1989-09-30 1998-10-15 財団法人化学及血清療法研究所 イヌ免疫グロブリンκ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JP2837240B2 (ja) * 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JP2811089B2 (ja) * 1989-08-25 1998-10-15 財団法人化学及血清療法研究所 イヌ×マウスヘテロハイブリドーマおよびイヌ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
ATE228536T1 (de) 1993-03-11 2002-12-15 Tanox Biosystems Inc Antigene epitope von ige repräsentierenden peptiden auf der b-zell-oberfläche aber nicht auf oberflächen von basophilen
US5629415A (en) 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
AU1146897A (en) 1995-12-08 1997-06-27 Idexx Laboratories, Inc. Methods and compositions concerning allergy in dogs
US5945294A (en) 1996-11-26 1999-08-31 Heska Corporation Method to detect IgE
US6060326A (en) 1997-04-07 2000-05-09 Heska Corporation Method to detect canine IgE and kit therefor
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
ES2234180T3 (es) 1998-04-09 2005-06-16 Idexx Laboratories, Inc. Proteinas de fijacion especifica para el tratamiento de la alergia canina.
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
JP2003521916A (ja) 2003-07-22
AU2001233102A1 (en) 2001-08-14
DE60127237D1 (de) 2007-04-26
JP4605973B2 (ja) 2011-01-05
US6504013B1 (en) 2003-01-07
EP1254180B1 (en) 2007-03-14
EP1254180A1 (en) 2002-11-06
WO2001057090A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
DE60127237T2 (de) Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie
DE69312077T2 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
DE60034579T3 (de) Baff rezeptor (bcma), ein immunoregulatorisches mittel
DE69533331T2 (de) Liganden zur induktion der antigen-spezifischen apoptose in t-zellen
DE69838061T2 (de) Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
DE69229428T2 (de) Therapeutisch nützliche peptide und peptidfragmente
DE69433820T2 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
DE3686927T2 (de) Neovaskularisierungsinhibitoren und deren herstellung.
DE69633617T3 (de) Il-17 receptor
DE69129302T2 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
DE60126980T2 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69014474T2 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
DE69624116T2 (de) Verfahren zur behandlung von allergischem asthma
DE69230733T3 (de) Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen
DE60217698T2 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
DE69126607T2 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
DE69632681T2 (de) Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
DE3751553T2 (de) Immunomodulare mittel und deren verwendung.
DE69736835T2 (de) Antikörper gegen den interferon-alpha/beta-rezeptor.
DE69328025T2 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE60125563T2 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
DE69535713T2 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
DE68908431T2 (de) Methode zur Verminderung der Immunglobulin-E-Reaktion.
DE69931944T2 (de) Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges

Legal Events

Date Code Title Description
8364 No opposition during term of opposition